Dupilumab significantly reduced severe asthma exacerbations and improved prebronchodilator FEV1 in patients with baseline FeNO greater than or equal to 25 ppb with/without substantial FeNO reduction.
Your search for severe asthma returned 398 results
Tezepelumab is an investigational first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
Findings from a phase 3b trial showed that a majority of patients with severe eosinophilic asthma treated with benralizumab (Fasenra; AstraZeneca), an interleukin-5 antagonist, were able to eliminate or reduce oral corticosteroid (OCS) use. The open-label, single-arm PONENTE trial assessed the efficacy and safety of reducing OCS use after initiating treatment with benralizumab in nearly…
The randomized, double-blind, placebo-controlled VOYAGE trial included 408 children aged 6 to 11 years with uncontrolled persistent asthma.
The first-in-class tyrosine kinase inhibitor masitinib decreased asthma exacerbations greater than placebo in patients with severe asthma uncontrolled by oral corticosteroids.
Treatment with mepolizumab is associated with improvements in asthma exacerbation rates and health-related quality of life in patients with severe eosinophilic asthma and comorbid nasal polyps, sinusitis, or allergic rhinitis.
Among patients with severe asthma, benralizumab treatment improved nasal symptoms, which worsen with increasing baseline blood eosinophil count.
Treatment with masitinib, a selective tyrosine kinase inhibitor, significantly reduces the rate of severe asthma exacerbations in patients with severe asthma uncontrolled by oral corticosteroids, according to data from a phase 3 study.
The study was designed to examine the prescribing patterns at a large academic teaching center to identify patients who have taken more than one biologic asthma medication, either sequentially or simultaneously, and to analyze the outcomes.
In the asthma clinical trials, the most common adverse reactions were injection site reactions, oropharyngeal pain, and eosinophilia.